+86 400-821-9890


By utilizing our big panel comprehensive genomic
profiling test, we collaborate with our partners in
biomarker discovery and biomarker-driven drug
development-from target discovery to
commercial launch.

Fusion-Based Biomarkers
for Targeted Therapy

We have integrated DNA and RNA sequencing results
for detection of fusion genes with higher sensitivity.

DNA+RNA-based analysis
of Fusion

RNA sequencing is a supplement to fusion detection

In Chinese solid tumor cohort, 60.2% of fusion could be identified both in DNA&RNA, 21.4% of fusion was DNA only and 18.4% was RNA only.

Gene fusions

Overview of gene rearrangement in Chinese cohort including kinase gene fusions and LOF rearrangement of tumor suppressor genes. Different driver genes and their partners were identified in the cohort. The thickness of the line indicated the number of cases with relative gene rearrangement.

NTRK family gene fusions

Among 5,388 clinical cases, 22 ( 0.4% ) patients were found harboring NTRK1/3 fusions by next-generation sequencing testing, which was further confirmed by pan-Trk IHC or PCR.
NTRK fusions were detected more in fibrosarcoma and colorectal cancer at a ratio of 11.1% and 1.1%, respectively.

FGFR family gene fusions

From over 4,000 solid tumor patients, 6.6% had FGFR 1-4 variations. The incidences of genomic alterations on FGFR1, 2, 3, and 4 were 2.8%, 1.6%, 1.2% and 1%, respectively. Amplification was the most common variation type of FGFR, which accounted for 47% of all the genomic alterations, followed by mutations (41.5%) and fusions (11.4%).

Targeted Therapy


The 5000+ Chinese solid tumor patients included 58.3% males and 41.7% females. Among patients with BRCA1/2 mutations,74.7% patients harbored somatic mutations. 24.3% patients harbored germline mutations and 1.0% patients harbored both somatic and germline mutations.


Distriution and frequency of ERBB2 variants in 5000+ Chinese solid tumor patients.


We have leveraged multiple techniques (DNA, RNA, IHC, etc.) to help identify
immunotherapy-related biomarkers for our patients.


The landscape of tumor mutational burden (TMB)in 10,000+ Chinese solid tumor patients.


The landscape of PD-L1 expression on varoius types of tumor cells in 3,000+ Chinese solid tumor patients.